



[54] **MONOCLONAL ANTIBODIES DIRECTED TO THE HER2 RECEPTOR**

[75] Inventors: **Robert M. Hudziak**, Corvallis, Oreg.; **H. Michael Shepard**, Rancho Santa Fe, Calif.; **Axel Ullrich**, Portola Valley, Calif.; **Brian M. Fendly**, Half Moon Bay, Calif.

[73] Assignee: **Genentech, Inc.**, South San Francisco, Calif.

[\*] Notice: The term of this patent shall not extend beyond the expiration date of Pat. No. 5,725,856, and 5,720,954.

[21] Appl. No.: **447,517**

[22] Filed: **May 23, 1995**

**Related U.S. Application Data**

[63] Continuation of Ser. No. 286,303, Aug. 5, 1994, Pat. No. 5,677,171, which is a continuation of Ser. No. 977,453, Nov. 18, 1992, abandoned, which is a continuation of Ser. No. 147,461, Jan. 25, 1988, abandoned, which is a continuation-in-part of Ser. No. 143,912, Jan. 12, 1988, abandoned.

[51] **Int. Cl.**<sup>6</sup> ..... **A61K 39/395**; C07K 16/30; C07K 16/46; C12P 21/08

[52] **U.S. Cl.** ..... **424/130.1**; 424/133.1; 424/134.1; 424/142.1; 424/143.1; 424/155.1; 424/156.1; 424/174.1; 424/183.1; 530/388.22; 530/387.3; 530/387.7; 530/388.8

[58] **Field of Search** ..... 424/130.1, 183.1, 424/174.1, 156.1, 155.1, 143.1, 142.1, 134.1, 133.1; 530/388.22, 387.3, 387.7, 388.8

[56] **References Cited****U.S. PATENT DOCUMENTS**

4,699,877	10/1987	Cline et al. .	
4,753,894	6/1988	Frankel et al. .	
4,906,646	3/1990	Honn et al. ....	514/356
4,943,533	7/1990	Mendelsohn et al. .	
4,957,735	9/1990	Huang .....	424/85.8
4,968,603	11/1990	Slamon et al. .	
5,108,934	4/1992	Rokugawa et al. .	
5,470,571	11/1995	Herlyn et al. .	

**FOREIGN PATENT DOCUMENTS**

359282 A2	3/1990	European Pat. Off. .	
239400	8/1994	European Pat. Off. ....	C12N 15/00
667165 A1	8/1995	European Pat. Off. .	
60-243027	12/1985	Japan .	
62-108157	5/1987	Japan .	
WO 85/03357	8/1985	WIPO .....	G01N 33/574
WO 87/07646	12/1987	WIPO .	
WO 89/10412	11/1989	WIPO .....	C12Q 1/68

**OTHER PUBLICATIONS**

Akiyama et al., "Potentiation of Cytotoxic Activity of Immunotoxins on Cultured Human Cells" *Cancer Research* 45:1005-1007 (1985).

Akiyama et al., "The product of the human c-erbB-2 Gene: a 185-Kilodalton Glycoprotein with tyrosine Kinase Activity" *Science* 232:1644-1646 (1986).

Coussens et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene" *Science* 230:1132-1139 (1985).

Douillard et al., "Radioimmunotetection of Human Tumors with Radiolabeled Monoclonal Antibodies" *Oncogenes to Tumor Antigens*, Geraldo et al. (eds.), Elsevier Sci. Publ. (1985).

Drebin et al., "Development of Monoclonal Antibodies Reactive with the Product of the neu Oncogene" *Symposium on Fundamental Cancer Research* 38:277-289 (1986).

Drebin et al., "Down-Modulation of an Oncogene Protein Product an Reversion of the Transformed Phenotype by Monoclonal Antibodies" *Cell* 41(3):695-706 (1985).

Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen" *Proc. Natl. Acad. Sci.* 83:9129-9133 (1986).

Drebin et al., "Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene" *Nature* 312:545-548 (1984).

Fendly et al., "Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product" *Cancer Research* 50:1550-1558 (1990).

Fukushige et al., "Localization of a Novel v-erbB-Related Gene, c-erbB-2, on Human Chromosomes 17 and its Amplification in a Gastric Cancer Cell Line" *Molecular & Cellular Biology* 6(3):955-58 (1986).

Gill et al., "Monoclonal Anti-epidermal Growth Factor Receptor Antibodies Which are Inhibitors of Epidermal Growth Factor Binding and Antagonists of Epidermal Growth Factor-stimulated Tyrosine Kinase Activity" *Journal of Biological Chemistry* 259:7755-60 (1984).

Hudziak et al., "Increased expression of the putative growth factor receptor p185<sup>HER2</sup> causes transformation and tumorigenesis of NIH 3T3 cells" *Proc. Natl. Acad. Sci.* 84:7159-7163 (1987).

Hudziak et al., "p185<sup>HER2</sup> Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" *Molecular & Cellular Biology* 9(3):1165-1172 (1989).

King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" *Science* 229:974-976 (1985).

(List continued on next page.)

*Primary Examiner*—Lila Feisee  
*Assistant Examiner*—Geetha P. Bansal  
*Attorney, Agent, or Firm*—Wendy M. Lee

[57] **ABSTRACT**

A method of inhibiting growth of tumor cells which over-express a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.

**36 Claims, 6 Drawing Sheets**

## OTHER PUBLICATIONS

- Kipps et al., "Schemata for the production of monoclonal antibody-producing hybridomas" *Handbook of Experimental Immunology*, Herzenberg et al. (eds.), Blackwell Sci., Chapter 108, pps. 108.1–108.9 (1986).
- Lupu et al., "Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and P185<sup>erbB2</sup>" *Science* 249:1552–1555 (1990).
- Mansi et al., "In vivo Evaluation of an Anti-Melanoma Antibody, F(ab')<sub>2</sub>, Labelled with TC-99m" *Oncogenes to Tumor Antigens*, Geraldo et al., eds., Elsevier Sci. Publ. (1985).
- Masui et al., "Mechanism of Antitumor Activity in Mice for Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies with Different Isotypes" *Cancer Research* 46:5592–5598 (1986).
- McKenzie et al., "Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185" *Oncogene* 4:543–548 (1989).
- Morrison, "Transfectomas Provide Novel Chimeric Antibodies" *Science* 229:1202–1207 (1985).
- Muller et al., "Single-Step Induction of Mammary Adenocarcinoma in Transgenic Mice Bearing the Activated c-neu Oncogene" *Cell* 54:105–115 (1988).
- Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185<sup>neu</sup>" *Methods in Enzymology* 198:277–290 (1991).
- Padhy et al., "Identification of a Phosphoprotein Specifically Induced by the Transforming DNA of Rat Neuroblastomas" *Cell* 28:865–871 (1982).
- Rodeck et al., "Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors" *J. Cellular Biochem.* 35(4):315–320 (1987).
- Rodeck et al., "Tumor Growth Modulation by a Monoclonal Antibody to the Epidermal Growth Factor Receptor: Immunologically Mediated and Effector Cell-independent Effects" *Cancer Research* 47(14):3692–3696 (1987).
- Rosenthal et al., "Expression in Rat Fibroblasts of a Human Transforming Growth Factor- $\alpha$  cDNA Results in Transformation" *Cell* 46:301–309 (1986).
- Sato et al., "Biological Effects in Vitro of Monoclonal Antibodies to Human Epidermal Growth Factor Receptors" *Mol. Biol. Med.* 1:511–529 (1983).
- Schechter et al., "The neu Gene: An erbB-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF Receptor" *Science* 229:976–978 (1985).
- Schlom et al., "Basic Principles and Applications of Monoclonal Antibodies on the Management of Carcinomas: The Richard and Hinda Rosenthal Foundation Award Lecture" *Cancer Research* 46:3225–3238 (1986).
- Semba et al., "A v-erbB-related protooncogene c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma" *Proc. Natl. Acad. Sci. USA* 82:6497–6501 (1985).
- Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" *Science* 235:177–182 (1987).
- Sobol et al., "Epidermal Growth Factor Receptor Expression in Human Lung Carcinomas Defined by a Monoclonal Antibody" *J. Natl. Cancer Institute* 79(3):403–407 (1987).
- Sugarman et al., "Effects of Growth Factors on the Antiproliferative Activity of Tumor Necrosis Factor" *Cancer Research* 47:780–786 (1987).
- Sugarman et al., "Recombinant Human Tumor Necrosis Factor- $\alpha$ : Effects on Proliferation of Normal and Transformed Cells in Vitro" *Science* 230:943–945 (1985).
- Takahashi et al., "Radioimmunodetection of Human Glioma Xenografts by Monoclonal Antibody to Epidermal Growth Factor Receptor" *Cancer Reserch* 47:3847–3850 (1987).
- Urban et al., "Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages" *Proc. Natl. Acad. Sci.* 83:5233–5237 (1986).
- Van de Vijver et al., "Amplification of the neu (c-erbB-2) Oncogene in Human Mammary Tumors Is Relatively Frequent and Is Often Accompanied by Amplification of the Linked c-erbA Oncogene" *Molecular & Cellular Biology* 7(5):2019–2023 (1987).
- Venter et al., "Overexpression of the c-erbB-2 Oncoprotein in Human Breast Carcinomas: Immunohistological Assessment Correlates with Gene Amplification" *Lancet* pps. 69–72 (1987).
- Vitetta et al., "Redesigning nature's poisons to create anti-tumor reagents" *Science* 238:1098–1104 (1987).
- Vollmar et al., "Toxicity of Ligand and Antibody-Directed Ricin A-Chain Conjugates Recognizing the Epidermal Growth Factor Receptor" *J. Cellular Physiology* 131:418–425 (1987).
- Yamamoto et al., "Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor" *Nature* 319:230–34 (1986).
- Aboud-Pirak et al., "Efficacy of Antibodies to Epidermal Growth Factor Receptor Against KB Carcinoma In Vitro and in Nude Mice" *Journal of the National Cancer Institute* 80(20):1605–1611 (Dec. 21, 1988).
- Ballet et al., "Evaluation of a Nude Mouse-Human Tumor Panel as a Predictive Secondary Screen for Cancer Chemotherapeutic Agenst" *J. Natl. Canc. Inst* 63(5):1185–1188 (1979).
- Bernards et al., "Effective Tumor Immunotherapy Directed Against an Oncogene-encoded Product Using a Vaccinia Virus Vector" *Proc. Natl. Acad. Sci. USA* 84:6854–6858 (Oct. 1987).
- Bucholtz, J.D., "Radiolabeled Antibody Therapy" *Semin. Oncol. Nurs.* (abstract only) 3(1):67–73 (1987).
- Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" *Oncogene* 2:273–277 (1988).
- Hancock et al., "A Monoclonal Antibody Against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum Against Human Breast and Ovarian Tumor Cell Lines" *Cancer Research* 51:4575–4580 (Sep. 1, 1991).
- Masuko et al., "A murine Monoclonal Antibody That Recognizes an Extracellular Domain of the Human c-erbB-2 Protooncogene Product" *Jpn J. Cancer Res.* 80:10–14 (Jan. 1989).
- Park et al., "Development of anti-p185<sup>HER2</sup> Immunoliposomes for Cancer Therapy" *Proc. Natl. Acad. Sci. USA* 92:1327–1331 (Feb. 1995).
- Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" *Nature* 312:724–729 (1984).
- Ring et al., "Identity of BCA200 and c-erbB-2 Indicated by Reactivity of Monoclonal Antibodies with Recombinant c-erbB-2" *Molecular Immunology* 28(8):915–917 (1991).

Arteaga et al., "Antibodies Against p185/HER2 Enhance Etoposide-Induced Cytotoxicity Against Human Breast Carcinoma Cells" *Proceedings of ASCO-29th Annual Meeting* (Abstract #101), Orlando, FL 12:75 (1993).

Bargmann et al., "Multiple Independent Activations of the neu Oncogene by a Point Mutation Altering the Transmembrane Domain of p185" *Cell* 45:649-659 (Jun. 6, 1986).

Baselga et al., "Anti Her2 Humanized Monoclonal Antibody (MAb) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts" *Proceedings of ASCO-13th Annual Meeting* (Abstract #53), Dallas, TX 13:63 (1994).

Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185/HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" *J. Clin. Oncol.* 14(3):737-744 (1996).

Baselga et al., "Receptor Blockade With Monoclonal Antibodies as Anti-Cancer Therapy" *Pharmac. Ther.* 64:127-154 (1994).

Beguinet et al., "Down-Regulation of the Epidermal Growth Factor Receptor in KB Cells is Due to Receptor Internalization and Subsequent Degradation in Lysozymes" *Proc. Natl. Acad. Sci. USA* 81(8):2384-2388 (1984).

De Santes et al., "Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein-I" *Cancer Research* 52:1916-1923 (1992).

Lyall et al., "EGF Induces Receptor Down-regulation with No Receptor Recycling in KB Cells" *J. Cell Physiol* 122(1):166-170 (1985).



Pegram et al., "Monoclonal Antibody to HER-2/neu Gene Product Potentiates Cytotoxicity of Carboplatin and Doxorubicin in Human Breast Tumor Cells" *Proceedings of the American Assoc. for Cancer Research* (Abstract # 2639-83rd Annual Meeting), San Diego, CA 33:442 (1992).

Pegram et al., "Phase II Study of Intravenous Recombinant Humanized Anti-p185 Monoclonal" *Proceedings of the ASCO-31st Annual Meeting* (Abstract #124), Los Angeles, CA 14:106 (1995).

Pietras et al., "Antibody to HER-2/neu Receptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells" *Oncogene* 9:1829-1838 (1994).

Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" *J. Clin. Immunol.* 11(3):117-127 (1991).

Taetle et al., "Effects of Anti-Epidermal Growth Factor (EGF) Receptor Antibodies and an Anti EGF Receptor Rocombinant-ricin A Chain Immunoconjugate on Growth of Human Cells" *J. Natl. Cancer Institute* 80(13):1053-1059 (1988).



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.